A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Dexcom Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 25,858 shares of DXCM stock, worth $2.08 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
25,858
Previous 29,646 12.78%
Holding current value
$2.08 Million
Previous $3.36 Million 48.41%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$64.0 - $116.06 $242,432 - $439,635
-3,788 Reduced 12.78%
25,858 $1.73 Million
Q2 2024

Jul 26, 2024

SELL
$110.31 - $140.45 $2.38 Million - $3.04 Million
-21,619 Reduced 42.17%
29,646 $3.36 Million
Q1 2024

Apr 24, 2024

SELL
$114.22 - $140.1 $1.9 Million - $2.34 Million
-16,667 Reduced 24.53%
51,265 $7.11 Million
Q4 2023

Feb 09, 2024

BUY
$75.49 - $124.16 $3.13 Million - $5.15 Million
41,469 Added 156.71%
67,932 $8.43 Million
Q3 2023

Oct 24, 2023

BUY
$86.06 - $137.93 $449,405 - $720,270
5,222 Added 24.58%
26,463 $2.47 Million
Q2 2023

Jul 13, 2023

SELL
$112.47 - $130.98 $1.49 Million - $1.73 Million
-13,221 Reduced 38.36%
21,241 $2.73 Million
Q1 2023

May 11, 2023

BUY
$104.0 - $122.92 $954,928 - $1.13 Million
9,182 Added 36.32%
34,462 $4 Million
Q4 2022

Feb 08, 2023

BUY
$84.98 - $122.67 $310,686 - $448,481
3,656 Added 16.91%
25,280 $2.86 Million
Q3 2022

Oct 17, 2022

BUY
$76.35 - $94.18 $82,610 - $101,902
1,082 Added 5.27%
21,624 $1.74 Million
Q2 2022

Jul 13, 2022

BUY
$67.99 - $132.89 $993,741 - $1.94 Million
14,616 Added 246.64%
20,542 $1.53 Million
Q1 2022

May 12, 2022

SELL
$94.08 - $130.2 $135,381 - $187,357
-1,439 Reduced 19.54%
5,926 $757,000
Q4 2021

Feb 03, 2022

SELL
$129.87 - $162.82 $153,116 - $191,964
-1,179 Reduced 13.8%
7,365 $988,000
Q3 2021

Nov 02, 2021

BUY
$106.71 - $143.18 $145,659 - $195,440
1,365 Added 19.01%
8,544 $1.17 Million
Q2 2021

Aug 10, 2021

SELL
$80.99 - $107.93 $45,597 - $60,764
-563 Reduced 7.27%
7,179 $766,000
Q1 2021

May 07, 2021

BUY
$84.79 - $104.74 $178,059 - $219,954
2,100 Added 37.22%
7,742 $695,000
Q4 2020

Feb 04, 2021

BUY
$78.0 - $104.5 $32,994 - $44,203
423 Added 8.11%
5,642 $521,000
Q3 2020

Oct 29, 2020

SELL
$95.51 - $112.95 $155,872 - $184,334
-1,632 Reduced 23.82%
5,219 $537,000
Q2 2020

Jul 27, 2020

BUY
$62.68 - $105.34 $152,688 - $256,608
2,436 Added 55.18%
6,851 $694,000
Q1 2020

May 08, 2020

BUY
$47.79 - $75.63 $41,194 - $65,193
862 Added 24.26%
4,415 $297,000
Q4 2019

Feb 04, 2020

SELL
$36.62 - $57.29 $31,676 - $49,555
-865 Reduced 19.58%
3,553 $194,000
Q3 2019

Nov 06, 2019

SELL
$35.53 - $43.8 $7,994 - $9,855
-225 Reduced 4.85%
4,418 $164,000
Q3 2019

Oct 28, 2019

BUY
$35.53 - $43.8 $2,380 - $2,934
67 Added 1.46%
4,643 $173,000
Q2 2019

Aug 15, 2019

SELL
$27.84 - $38.92 $57,656 - $80,603
-2,071 Reduced 31.16%
4,576 $0
Q1 2019

May 08, 2019

BUY
$28.07 - $38.18 $77,894 - $105,949
2,775 Added 71.67%
6,647 $0
Q4 2018

Feb 05, 2019

SELL
$26.99 - $37.37 $9,095 - $12,593
-337 Reduced 8.01%
3,872 $115,000
Q3 2018

Nov 02, 2018

BUY
$23.35 - $36.72 $98,280 - $154,554
4,209 New
4,209 $0

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $31.1B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.